BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ddaysoftware.com//NONSGML DDay.iCal 1.0//EN
BEGIN:VEVENT
DESCRIPTION:The introduction of anti-VEGF agents for the treatment of age-r
 elated macular degeneration (AMD)\, diabetic retinopathy (DR)\, and retina
 l vein occlusion (RVO)\, transformed the management of these conditions. W
 hile the clinical benefits of these compounds are well documented their us
 e brings up other issues for ophthalmologists\, namely\, cost. Thus\, paye
 rs have become more involved in managing the use of these agents\, potenti
 ally interfering with clinical decision making. This live event brings tog
 ether thought leaders in the retina field to discuss the challenges they f
 ace in obtaining access to anti-VEGF medications for their patients\, and 
 how they overcome those challenges.\nContact: Alan Guralnick\; alan@evolve
 meded.comWeb URL: https://bmcg.regfox.com/2019-evolve-market-access
DTEND:20190331T013000Z
DTSTAMP:20260922T170513
DTSTART:20190330T233000Z
LOCATION:Four Seasons Dallas at Las Colinas Irving\, Texas 
SEQUENCE:0
SUMMARY:What’s Changing in 2019: Market Access Challenges with Anti-VEGF Th
 erapies
UID:a5ff35d9-6f41-4c5c-9b93-1ad417943168
END:VEVENT
END:VCALENDAR